Hologic's Diagnostics Performance: Hologic's Diagnostics segment has shown resilience despite macroeconomic challenges, with a 1.5% revenue increase in Q4 2025, driven by U.S. molecular diagnostics sales and the continued success of the BV, CV/TV vaginitis assay.
Future Growth Drivers: The Panther Fusion platform is expected to enhance future growth in diagnostics due to its efficiency and flexibility, while recent CE Mark and FDA approvals for new assays bolster Hologic's market position.
Abbott's Product Expansion: Abbott has launched its Lingo continuous glucose monitor for Android devices, expanding access to real-time glucose data, and introduced new Ensure Max protein shakes to cater to the muscle health trend.
Roche's IVD Advancements: Roche received CE Mark approval for its mass spectrometry reagent pack and the cobas BV/CV assay, enhancing its in-vitro diagnostics offerings and solidifying its position in the market.
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 77.56 USD with a low forecast of 76.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 77.56 USD with a low forecast of 76.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
12 Hold
0 Sell
Hold
Current: 75.110
Low
76.00
Averages
77.56
High
79.00
Current: 75.110
Low
76.00
Averages
77.56
High
79.00
Evercore ISI
Outperform -> In Line
downgrade
$79 -> $78
2026-01-05
Reason
Evercore ISI
Price Target
$79 -> $78
AI Analysis
2026-01-05
downgrade
Outperform -> In Line
Reason
Evercore ISI downgraded Hologic to In Line from Outperform with a price target of $78, down from $79.
BNP Paribas Exane
Outperform -> Neutral
downgrade
$79
2025-11-21
Reason
BNP Paribas Exane
Price Target
$79
2025-11-21
downgrade
Outperform -> Neutral
Reason
BNP Paribas Exane downgraded Hologic to Neutral from Outperform with a $79 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HOLX
Unlock Now
Morgan Stanley
Equal Weight
maintain
$69 -> $76
2025-11-10
Reason
Morgan Stanley
Price Target
$69 -> $76
2025-11-10
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Hologic (HOLX) to $76 from $69 and keeps an Equal Weight rating on the shares after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The firm views the proposed acquisition price as "a fair valuation" and doesn't expect any barriers to the transaction closing in the first half of 2026, the analyst tells investors.
Mizuho
Outperform -> Neutral
downgrade
$78
2025-10-23
Reason
Mizuho
Price Target
$78
2025-10-23
downgrade
Outperform -> Neutral
Reason
Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
